Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)

被引：10

作者：

Antonia, Scott ^{[1
]}

Rizvi, Naiyer ^{[2
]}

Brahmer, Julie ^{[3
]}

Ou, Sai-Hong ^{[4
]}

Khleif, Samir N. ^{[5
]}

Hwu, Wen-Jen ^{[6
]}

Gutierrez, Martin ^{[7
]}

Schoffski, Patrick ^{[8
]}

Hamid, Omid ^{[9
]}

Weiss, Jared ^{[10
]}

Lutzky, Jose ^{[11
]}

Maio, Michele ^{[12
]}

Nemunaitis, John ^{[13
]}

Jaeger, Dirk ^{[14
]}

Balmanoukian, Ani ^{[9
]}

Rebelatto, Marlon C. ^{[15
]}

Steele, Keith E. ^{[15
]}

Jin, Xiaoping ^{[15
]}

Robbins, Paul B. ^{[15
]}

Blake-Haskins, John A. ^{[15
]}

Segal, Neil H. ^{[16
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Columbia Univ, Med Ctr, New York, NY USA

[3] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[4] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA

[5] Georgia Regent Univ, GRU Canc Ctr, Agusta, MD USA

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[8] Leuven Canc Inst, Leuven, Belgium

[9] Angeles Clin & Res Inst, Los Angeles, CA USA

[10] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA

[11] Mt Sinai Med Ctr, New York, NY 10029 USA

[12] Univ Hosp Siena, Siena, Italy

[13] Mary Crowley Canc Res Ctr, Dallas, TX USA

[14] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany

[15] Medlmmune, Gaithersburg, MD USA

[16] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

CANCER IMMUNOLOGY RESEARCH | 2016年 / 4卷 / 01期

关键词：

D O I：

10.1158/2326-6074.CRICIMTEATIAACR15-A047

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A047

引用

页数：2

共 50 条

[21] Association Between Programmed Death Ligand-1 (PD-L1) Expression and Clinicopathological Features in Non-small Cell Lung Cancer (NSCLC)
Valcarcel Gonzalez, S.
Diaz, P.
Villanueva Palicio, N.
Alvarez Fernandez, C.
Contreras Toledo, D. C.
Mihic Gongora, L.
Rodriguez Gonzalez, A.
Velasco Durantez, V.
Solis Hernandez, M. D. P.
Esteban Gonzalez, E.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S569 - S570
[22] Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
Lee, Yong Jun
Lee, Jii Bum
Ha, Sang-Jun
Kim, Hye Ryun
MOLECULES AND CELLS, 2021, 44 (05) : 363 - 373
[23] Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC)
Velcheti, Vamsidhar
Schalper, Kurt
Carvajal, Daniel
Chen, Lieping
Sznol, Mario
Gettinger, Scott N.
Herbst, Roy S.
Rimm, David
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[24] Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.
Brahmer, Julie R.
Rizvi, Naiyer A.
Lutzky, Jose
Khleif, Samir
Blake-Haskins, Andy
Li, Xia
Robbins, Paul B.
Vasselli, Jim
Ibrahim, Ramy A.
Antonia, Scott Joseph
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[25] Programmed Death Ligand 1 (PD-L1) Expression in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
D'Arcangelo, M.
Puccetti, M.
Bravaccini, S.
D'Incecco, A.
Ligorio, C.
Terracciano, L.
Damiani, S.
Ravaioli, S.
Tumedei, M. M.
Bennati, C.
Minuti, G.
Vecchiarelli, S.
Landi, L.
Incarbone, M.
Milesi, M.
Cappuzzo, F.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2390 - S2390
[26] Assessing PD-L1 expression in Non-Small Cell Lung Cancer patients using68Ga-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody PET/CT
Chand, Gitasha
Cook, Gary
Hughes, Daniel
Meszaros, Levente
Wong, Nicholas
Ting, Honghoi
Zhao, Lingzhou
Xing, Yan
Zhao, Jinhua
JOURNAL OF NUCLEAR MEDICINE, 2020, 61
[27] Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
Mino-Kenudson, Mari
CANCER BIOLOGY & MEDICINE, 2016, 13 (02) : 157 - 170
[28] Programmed cell death ligand-1(PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
Mari Mino-Kenudson
Cancer Biology & Medicine, 2016, 13 (02) : 157 - 170
[29] Programmed cell death ligand-1(PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
Mari Mino-Kenudson
Cancer Biology & Medicine, 2016, (02) : 157 - 170
[30] Expression analysis of programmed cell death 1 ligand 1 (PD-L1) in patients with non-small cell lung cancer
Peng, Nanqiu
Qin, Liang
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2022, 15 (01): : 1 - 5

← 1 2 3 4 5 →